AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Effect of Super-GDF9 on CAPA-IVM of COCs From Small Antral Follicles

RecruitingNAAges 18 Years - 38 YearsFemaleMแปน ฤแปฉc Hospital
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

CAPA-IVM (In Vitro Maturation) technology is an assisted reproductive method offering significant benefits in terms of safety and treatment costs, particularly for high-risk patients. These include individuals with ovarian hyperstimulation syndrome (OHSS), venous thrombosis, ovarian torsion, or polycystic ovary syndrome (PCOS). However, while the live birth rate in the CAPA-IVM group (35.2%) is comparable to conventional IVF (43.2%), the number of good-quality embryos and cumulative clinical pregnancy rates remain lower. Improving the CAPA-IVM culture process, particularly through the addition of growth factors found in follicular fluid, has shown promise in enhancing oocyte quality. Growth differentiation factor 9 (GDF9) and Bone morphogenetic protein 15 (BMP15) play critical roles in follicular development, with their heterodimer structure demonstrating the most positive effects on cu

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Women between the ages of 18 and 38 years (both inclusive) 2. BMI โ‰ค 32 kg/m2 3. PCOS women according to the Rotterdam criteria (2003) 4. Indicating CAPA-IVM treatment. 5. Serum AMH โ‰ฅ 4 ng/mL (28.57 pmol/L) at screening and having at least 24 antral follicles in two ovaries by transvaginal ultrasound at the time of CAPA-IVM indication 6. Willing to donate COCs for research purposes 7. Agreeing for frozen embryo 8. Signed informed consent before any study-related procedures Exclusion Criteria: 1. Known endometrioma or grade 3-4 endometriosis according to ASRM classification 2. Uterine abnormalities 3. Couples with severe male factor (sperm concentration \<5 million/ml, motility \< 10%), surgical sperm retrieval. 4. Previous history of unexplained immature oocytes after IVF treatment 5. Cycles using donor oocytes
๐Ÿ’Š

What it tests

  • Super-GDF9 supplementation during CAPA-IVM
  • Conventional CAPA-IVM
๐Ÿ“

Where

1 site
My Duc Hospital
Ho Chi Minh City, Vietnam
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy